High Risk Smoldering Multiple Myeloma Clinical Trials in Boston, Massachusetts
2 recruitingBoston, Massachusetts
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals270 enrolled1 locationNCT07393282
Recruiting
Phase 2
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Multiple MyelomaSmoldering Multiple MyelomaHigh Risk Smoldering Multiple Myeloma
Irene Ghobrial, MD52 enrolled3 locationsNCT05469893